A review of the ethnic differences in breast cancer

Pharmacogenomics

Volumn 7, Issue 6, 2006, Pages 935-942

  Bowen, Rebecca L ^a   Stebbing, J ^b   Jones, L J ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

African American women; Basal like phenotype; BRCA1 similarities; Estrogen receptor negativity; Ethnic differences; HRAS1 proto oncogene expression; Invasive breast cancer; P53 mutations; White Caucasian women

Indexed keywords

ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; HORMONE; HYDRALAZINE; ISOSORBIDE DINITRATE; PACLITAXEL; PROGESTERONE RECEPTOR; PROTEIN P53; TAMOXIFEN; TUMOR MARKER;

ADVANCED CANCER; AFRICAN AMERICAN; AGE; ALLELE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CAUCASIAN; CLINICAL TRIAL; DRUG METABOLISM; ETHNIC DIFFERENCE; GENE EXPRESSION; GENE MUTATION; GENETIC POLYMORPHISM; HEART FAILURE; HUMAN; LEUKOCYTE COUNT; META ANALYSIS; NEGRO; ONCOGENE H RAS; PROGNOSIS; PROTO ONCOGENE; REVIEW; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM;

AFRICAN AMERICANS; AFRICAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENES, BRCA1; GENES, BRCA2; GENES, P53; GENES, RAS; HUMANS; MUTATION; PHARMACOGENETICS; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 33749013547     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.7.6.935     Document Type: Review

References (69)

1. Brawley OW: Disaggregating the effects of race and poverty on breast cancer outcomes. J. Natl Cancer Inst. 94(7), 471-413 (2002).
2. Elledge RM, Clark GM, Chamness GC et al.: Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J. Natl Cancer Inst. 86(9), 705-712 (1994).
3. Jatoi I, Anderson WF, Rao SR et al.: Breast cancer trends among black and white women in the United States. J. Clin. Oncol. 23(31), 7836-7841 (2005).
4. Adebamowo CA, Adekunle OO: Case-controlled study of the epidemiological risk factors for breast cancer in Nigeria. Br. J. Surg. 86(5), 665-668 (1999).
5. Newman LA, Alfonso EA: Age-related differences in breast cancer stage at diagnosis between black and white patients in an urban community hospital. Ann. Surg. Oncol. 4(8), 655-662 (1997).
6. Steele GD Jr.: The National Cancer Data Base report on colorectal cancer. Cancer 74(7), 1979-1989 (1994).
7. El-Tamer MB, Homel P, Wait BR: Is race a poor prognostic factor in breast cancer? J. Am. Coll. Surg. 189(1), 41-45 (1999).
8. Joslyn SA, West MM: Racial differences in breast carcinoma survival. Cancer 88(1), 114-123 (2000).
9. Newman LA, Bunner S, Carolin K et al.: Ethnicity related differences in the survival of young breast carcinoma patients. Cancer 95(1), 21-27 (2002).
10. Jones BA, Kasl SV. Howe CL et al.: African-American/White differences in breast carcinoma: p53 alterations and other tumor characteristics. Cancer 101(6), 1293-1301 (2004).
11. Gukas ID, Jennings BA, Mandong BM et al.: Clinicopathological features and molecular markers of breast cancer in Jos, Nigeria. West Afr. J. Med. 24(3), 209-213 (2005).
12. Chang S, Parker SL, Pham T et al.: Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975-1992. Cancer 82(12), 2366-2372 (1998).
13. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50,302 women with breast cancer and 96,973 women without the disease. Lancet 360(9328), 187-195 (2002).
14. Okobia M, Bunker C, Zmuda J et al.: Case-control study of risk factors for breast cancer in Nigerian women. Int. J. Cancer
15. Selaru FM, Yin J, Olaru A et al.: An unsupervised approach to identify molecular phenotypic components influencing breast cancer features. Cancer Res. 64(5), 1584-1588 (2006).
16. Poola I, Clarke R, DeWitty R et al.: Functionally active estrogen receptor isoform profiles in the breast tumors of African-American women are different from the profiles in breast tumors of Caucasian women. Cancer 94(3), 615-623 (2002).
17. Carey LA, Perou CM, Livasy CA et al.: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295(21), 2492-2502 (2006).
18. Ameyaw MM, Tayeb M, Thornton N et al.: Ethnic variation in the HER2 codon 655 genetic polymorphism previously associated with breast cancer. J. Hum. Genet. 47(4), 172-175 (2002).
19. Vousden KH, X Lu: Live or let die: the cell's response to p53. Nat. Rev. Cancer 2(8), 594-604 (2002).
20. Lacroix M, Toillon RA, Leclercq G: p53 and breast cancer, an update. Endocr. Relat. Cancer 13(2), 293-325 (2006).
21. Feki A, Irminger-Finger I: Mutational spectrum of p53 mutations in primary breast and ovarian tumors. Crit. Rev. Oncol. Hematol. 52(2), 103-116 (2004).
22. Thor AD, Moore DH, II, Edgerton SM et al.: Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J. Natl Cancer Inst. 84(11), 845-855 (1992).
23. Weston, A. and Godbold HJ: Polymorphisms of H-ras-1 and p53 in breast cancer and lung cancer: a meta-analysis. Environ. Health Perspect. 105(Suppl.) 4, 919-926 (1997).
24. Olopade O, Weber BL: Breast cancer genetics: toward molecular characterization of individuals at increased risk for breast cancer. Part I. In: Cancer Priniciples and Practice of Oncology Updates. De Vita T, Hellman S. Rosenberg SA (Eds). Vol. 12. 1-12 (1998).
25. Goffin JR, Chappuis PO, Begin LR et al.: Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data. Cancer 97(3), 527-536 (2003).
26. Foulkes WD: BRCA1 functions as a breast stem cell regulator. J. Med. Genet. 41(1), 1-5 (2004).
27. Olopade OI, Fackenthal JD, Dunston G et al.: Breast cancer genetics in African-Americans. Cancer 97(1 Suppl.), 236-245 (2003).
28. Nanda R, Schumm LP, Cummings S et al.: Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. JAMA 294(15), 1925-1933 (2005).
29. Frank TS, Deffenbaugh AM, Reid JE et al.: Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J. Clin. Oncol. 20(6), 1480-1490 (2002).
30. Foulkes WD, Stefansson IM, Chappuis PO et al.: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J. Natl Cancer Inst. 95(19), 1482-1485 (2003).
31. Sorlie T, Perou CM, Tibshirani R et al.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98(19), 10869-10874 (2001).
32. Sorlie T, Tibshirani R, Parker J et al.: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA 100(14), 8418-8423 (2003).
33. Wetzels RH, Holland R, van Haelst UJ et al.: Detection of basement membrane components and basal cell keratin 14 in noninvasive and invasive carcinomas of the breast. Am. J. Pathol. 134(3), 571-579 (1989).
34. Arnes JB, Brunet JS, Stefansson I et al.: Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin. Cancer Res. 11(11), 4003-4011 (2005).
35. van de Rijn M, Perou CM, Tibshirani R et al.: Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am. J. Pathol. 161(6), 1991-1996 (2002).
36. Rouzier R, Perou CM, Symmans WF et al.: Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res. 11(16), 5678-5685 (2005).
37. Tsuda H, Takarabe T, Hasegawa F et al.: Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. Am. J. Surg. Pathol. 24(2), 197-202 (2000).
38. Mehrotra J, Ganpat MM, Kanaan Y et al.: Estrogen receptor/progesterone receptor-negative breast cancers of young African-American women have a higher frequency of methylation of multiple genes than those of Caucasian women. Clin. Cancer Res. 10(6), 2052-2057 (2004).
39. Hernandez J, Balic I, Johnson-Pais TL et al.: Association between an estrogen receptor alpha gene polymorphism and the risk of prostate cancer in black men. J. Urol. 175(2), 523-527 (2006).
40. Canter JA, Kallianpur AR, Parl FF et al.: Mitochondrial DNA G10398A polymorphism and invasive breast cancer in African-American women. Cancer Res. 65(17), 8028-8033 (2005).
41. Stackhouse BL, Williams H, Berry P et al.: Measurement of glut-1 expression using tissue microarrays to determine a race specific prognostic marker for breast cancer. Breast Cancer Res. Treat. 93(3), 247-253 (2005).
42. Bradley CJ, Given CW, Roberts C: Race, socioeconomic status, and breast cancer treatment and survival. J. Natl Cancer Inst. 94(7), 490-496 (2002).
43. Lannin DR, Mathews HF, Mitchell J et al.: Impacting cultural attitudes in African-American women to decrease breast cancer mortality. Am. J. Surg. 184(5), 418-423 (2002).
44. Newman LA, Griffith KA, Jatoi I et al.: Meta-analysis of survival in African-American and white American patients with breast cancer: ethnicity compared with socioeconomic status. J. Clin. Oncol. 24(9), 1342-1349 (2006).
45. Newman LA, Theriault R, Clendinnin N et al.: Treatment choices and response rates in African-American women with breast carcinoma. Cancer 97(1 Suppl.), 246-252 (2003).
46. Hershman D, McBride R, Jacobson JS et al.: Racial disparities in treatment and survival among women with early-stage breast cancer. J. Clin. Oncol. 23(27), 6639-6646 (2005).
47. Bonadonna G, Valagussa P, Moliterni A et al.: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N. Engl. J. Med. 332(14), 901-906 (1995).
48. Bonadonna G, Valagussa P: Dose-response effect of adjuvant chemotherapy in breast cancer. N. Engl. J. Med. 304(1), 10-15 (1981).
49. Bickell NA, Wang JJ, Oluwole S et al.: Missed opportunities: racial disparities in adjuvant breast cancer treatment. J. Clin. Oncol. 24(9), 1357-1362 (2006).
50. Dignam JJ, Redmond CK, Fisher B et al.: Prognosis among African-American women and white women with lymph node negative breast carcinoma: findings from two randomized clinical trials of the National Surgical Adjuvant Breast and Bowel Project (NSABP). Cancer 80(1), 80-90 (1997).
51. Roach M III, Cirrincione C, Budman D et al.: Race and survival from breast cancer: based on Cancer and Leukemia Group B trial 8541. Cancer J. Sci. Am. 3(2), 107-112 (1997).
52. Dignam JJ: Differences in breast cancer prognosis among African-American and Caucasian women. CA Cancer J. Clin. 50(1), 50-64 (2000).
53. Briele HA Jr, Walker MJ, Wild L et al.: Results of treatment of stage I-III breast cancer in black Americans. The Cook County Hospital experience, 1973-1987. Cancer 65(5), 1062-1071 (1990).
54. Bain BJ: Ethnic and sex differences in the total and differential white cell count and platelet count. J. Clin. Pathol. 49(8), 664-666 (1996).
55. Smith K, Wray L, M. Klein-Cabral et al.: Ethnic disparities in adjuvant chemotherapy for breast cancer are not caused by excess toxicity in black patients. Clin. Breast Cancer 6(3), 260-269 (2005).
56. Gail MH, Costantino JP, Bryant J et al.: Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J. Natl Cancer Inst. 91(21), 1829-1846 (1999).
57. McCaskill-Stevens W, Wilson J, Bryant J et al.: Contralateral breast cancer and thromboembolic events in African-American women treated with tamoxifen. J. Natl Cancer Inst. 96(23), 1762-1769 (2004).
58. Albain K, Unger, JM, Hurchins LF et al.: Outcome of African-Americans on Southwest Oncology Group (SWOG) breast cancer adjuvant therapy trials. (abstr 21) San Antonio Breast Cancer Symposium. 2003. San Antonio, TX, USA.
59. Chlebowski RT, Chen Z, Anderson GL et al.: Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J. Natl Cancer Inst. 97(6), 439-448 (2005).
60. Taylor AL, Ziesche S, Yancy C et al.: Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N. Engl. J. Med. 351(20), 2049-2057 (2004).
61. Yancy CW, Fowler MB, Colucci WS et al.: Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N. Engl. J. Med. 344(18), 1358-1365 (2001).
62. Exner DV, Dries DL, Domanski MJ et al.: Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N. Engl. J. Med. 344(18), 1351-1357 (2001).
63. Lamba JK, Lin YS, Schuetz EG et al.: Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug Deliv. Rev. 54(10), 1271-1294 (2002).
64. Tucker AN, Tkaczuk KA, Lewis LM et al.: Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 217(1), 61-72 (2005).
65. Guillemette C, Millikan RC, Newman B et al.: Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African-Americans. Cancer Res. 60(4), 950-956 (2000).
66. Li Y, Millikan RC, Bell DA et al.: Cigarette smoking, cytochrome P4501A1 polymorphisms, and breast cancer among African-American and white women. Breast Cancer Res. 6(4), R460-R473 (2004).
67. Millikan RC, Player J, de Cotret AR et al.: Manganese superoxide dismutase Ala-9Val polymorphism and risk of breast cancer in a population-based case-control study of African-Americans and whites. Breast Cancer Res. 6(4), R264-R274 (2004).
68. Porter PL, Lund MJ, Lin MG et al.: Racial differences in the expression of cell cycle-regulatory proteins in breast carcinoma. Cancer 100(12), 2533-2542 (2004).
69. Shiao YH, Chen VW, Scheer WD et al.: Racial disparity in the association of p53 gene alterations with breast cancer survival. Cancer Res. 55(7), 1485-1490 (1995).